Channels

 

Special Offers & Promotions

 

 

Latest News

 

 

View Channel

New Products

 

 

View Channel

Video Presentations

 

 

View Channel

Separation Science

 

 

View Channel

Microscopy & Image Analysis

 

 

View Channel

Laboratory Automation & IT Solutions

 

 

View Channel

 

Waters Corporation Unveils MaxPeak Premier Oligonucleotide Columns

publication date: May 15, 2023
 | 
author/source: Waters Corporation

waters-corporation-unveils-maxpeak-premier 

New column technology essential for development of new cell and gene therapies and vaccines

Waters Corp introduces its newest MaxPeak Premier Oligonucleotide Columns – now with ethylene bridged hybrid (BEH) particle technology in 300Å wide pore versions – providing industry-leading chromatographic resolution for long-mer oligonucleotide separations to support applications for nucleic acid therapeutics and cell and gene therapies.

The new columns have all the benefits customers can expect from Waters’ MaxPeak Premier high performance surface chemistry and BEH particle technology – including enhanced sensitivity, reproducibility, and productivity with unmatched pH and temperature stability, which is essential for oligonucleotide/nucleic acid separations. The columns are available for both UPLC separations with Waters’ ACQUITY Premier Oligonucleotide BEH C18 columns and UHPLC/HPLC separations with Waters’ XBridge Premier Oligonucleotide BEH C18 columns.

Oligonucleotide analysis is changing with new modalities demanding more advanced technologies. Waters is a leader in oligonucleotide analysis with key methods and product developments that have advanced the field for more than 20 years.

New applications associated with nucleic acid therapeutics and vaccines require the ability to separate and analyze long-mer oligonucleotides, which was difficult to achieve with existing column technologies, until now. The Waters MaxPeak Premier Oligonucleotide BEH C18 300Å Columns enable high resolution separation of long-mer oligonucleotides. This means end users developing new gene-based therapeutics – such as mRNA poly(A) tail length and heterogeneity analysis for mRNA therapeutics and vaccines; single guide RNA (sgRNA) characterization for gene editing constructs; and mRNA oligo mapping and sequencing – can more quickly develop analytical methods and characterize the nucleic acid components of these drugs and their impurities.

Learn more about the new Premier Columns for oligonucleotide analysis

 

View Product Information

 

 

About Waters Corporation

Waters Corporation (NYSE: WAT), a global leader in analytical instruments and software, has pioneered chromatography, mass spectrometry, and thermal analysis innovations serving the life, materials, and food sciences for over 60 years. With more than 8,400 employees worldwide, Waters operates directly in 35 countries, including 14 manufacturing facilities, and with products available in more than 100 countries.

 

Recent news from Waters Corporation

 


If you have not logged into the website then please enter your details below.



 

News Channels

 

 

Subscribe to any of our newsletters for the latest on new laboratory products, industry news, case studies and much more!

Newsletters from Lab Bulletin

 

Request your free copies HERE

 

 

 

Popular this Month

Top 10 most popular articles this month

 

 

Today's Picks

 

 

 

 

Looking for a Supplier?

Search by company or by product

 


Company Name:

Product:


 

 

 

 

Please note Lab Bulletin does not sell, supply any of the products featured on this website. If you have an enquiry, please use the contact form below the article or company profile and we will send your request to the supplier so that they can contact you directly.

Lab Bulletin is published by newleaf marketing communications ltd.


 

Media Partners

 

Exhibitions & Events